| 1. |
|
|
| 2. |
- Ben-Menachem, Elinor, 1945, et al.
(författare)
-
Epilepsi
- 2011
-
Ingår i: Läkemedelsboken 2011-2012. - Uppsala. : Läkemedelsverket. - 9789197960502 ; , s. 965-76
-
Bokkapitel (refereegranskat)
|
|
| 3. |
- Ben-Menachem, Elinor, 1945
(författare)
-
Eslicarbazepine acetate: a well-kept secret?
- 2010
-
Ingår i: Epilepsy currents. - : SAGE Publications. - 1535-7511 .- 1535-7597. ; 10:1, s. 7-8
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in adults with ≥4 partial-onset seizures (simple or complex, with or without secondary generalization) per 4 weeks despite treatment with 1–2 antiepileptic drugs (AEDs). METHODS: This multicenter, parallel-group study had an 8-week, single-blind, placebo baseline phase, after which patients were randomized to placebo (n= 102) or once-daily ESL 400 mg (n= 100), 800 mg (n= 98), or 1,200 mg (n= 102) in the double-blind treatment phase. ESL starting dose was 400 mg; thereafter, ESL was titrated at weekly 400-mg steps to the full maintenance dose (12 weeks). RESULTS: Seizure frequency adjusted per 4 weeks over the maintenance period (primary endpoint) was significantly lower than placebo in the ESL 1,200-mg (p= 0.0003) and 800-mg (p= 0.0028) groups [analysis of covariance (ANCOVA) of log-transformed seizure frequency]. Responder rate was 20% (placebo), 23% (400 mg), 34% (800 mg), and 43% (1,200 mg). Median relative reduction in seizure frequency was 16% (placebo), 26% (400 mg), 36% (800 mg), and 45% (1,200 mg). The most frequent concomitant AEDs were carbamazepine (56–62% of patients), lamotrigine (25–27%), and valproic acid (22–28%). Similar efficacy results were obtained in patients administered ESL with or without carbamazepine as concomitant AED. Discontinuation rates caused by adverse events (AEs) were 3.9% (placebo), 4% (400 mg), 8.2% (800 mg), and 19.6% (1,200 mg). AEs in >10% of any group were dizziness, headache, and diplopia. Most AEs were mild or moderate. DISCUSSION: ESL, 800 and 1,200 mg once-daily, was well tolerated and more effective than placebo in patients who were refractory to treatment with one or two concomitant AEDs.
|
|
| 4. |
|
|
| 5. |
- Ben-Menachem, Elinor, 1945
(författare)
-
Introduction
- 2013
-
Ingår i: Acta Neurologica Scandinavica. - : Hindawi Limited. - 0001-6314. ; 127, s. 1-2
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Ben-Menachem, Elinor, 1945
(författare)
-
Medical management of refractory epilepsy-Practical treatment with novel antiepileptic drugs
- 2014
-
Ingår i: Epilepsia. - : Wiley. - 0013-9580. ; 55, s. 3-8
-
Tidskriftsartikel (refereegranskat)abstract
- The ultimate treatment goal in epilepsy therapy is always freedom from seizures with as few treatment adverse effects as possible. If seizures persist with the first monotherapy, alternative monotherapy with another antiepileptic drug (AED) should be considered. Continuing seizures should lead to a reevaluation of differential diagnosis and adherence. Epilepsy surgery as an alternative therapy may be suitable in selected cases. If the diagnosis of epilepsy is established and epilepsy surgery is not appropriate, AED treatment should be optimized. Evidence for how to proceed is lacking. Concepts such as rational polytherapy have been advocated but remain speculative concerning better efficacy based on the use of AEDs with differing modes of action. A variety of new AEDs including rufinamide, lacosamide, vigabatrin, perampanel, and retigabine have been recently introduced in the United States. They are briefly characterized in this update review.
|
|
| 9. |
- Ben-Menachem, Elinor, 1945
(författare)
-
Neurostimulation - Past, Present, and Beyond
- 2012
-
Ingår i: Epilepsy Currents. - : SAGE Publications. - 1535-7597 .- 1535-7511. ; 12:5, s. 188-191
-
Tidskriftsartikel (refereegranskat)abstract
- Neurostimulation as a treatment for epilepsy has been around for almost 20 years in the form of vagus nerve stimulation. Newer types of neurostimulation are being developed and stand on the brink of approval for use. The two newest therapies, not yet approved in the United States, are deep brain stimulation and the Responsive Neurostimulator System . In fact, in Europe, approval has already been given for deep brain stimulation and newer forms of vagus nerve stimulation. Efficacy is similar between these therapies, and side effects are moderate, so what will be the future? The challenge will be to learn how to use these therapies correctly and offer the right treatment for the right patient.
|
|
| 10. |
- Ben-Menachem, Elinor, 1945
(författare)
-
Vaccination and the onset of dravet syndrome.
- 2011
-
Ingår i: Epilepsy currents / American Epilepsy Society. - : SAGE Publications. - 1535-7511. ; 11:4, s. 120-2
-
Tidskriftsartikel (refereegranskat)
|
|
